IRWD

Fundamental analysis of Ironwood Pharmaceuticals reveals a moderate score of 5.7/10. Strengths include a high Gross profit margin at 100.0% and strong Profit-MV and Inventory turnover ratios. However, weaknesses such as a low Current assets turnover ratio and negative Asset-MV impact the composite view. The stock's valuation metrics place it in mixed quartiles, with Profit-MV in group 1 (score 2) and Cash-MV in group 2 (score 3), indicating room for improvement in asset and current asset utilization. Overall, the fundamentals are solid but not outstanding, supporting a neutral rating.